modified by inserting a membrane anchoring sequence so as to have a membrane location in the cells in which it is expressed.

22. The antitumoral composition according to claim 21, wherein said polypeptide naturally has a nuclear location and is, in addition, deleted for its natural nuclear localization sequence.

23. The antitumoral composition according to claim 21, wherein said membrane anchoring sequence is selected from the group consisting of rabies glycoprotein, HIV virus env glycoprotein, and measles virus F protein.

24. The antitumoral composition according to claim 21, wherein said immunogenic polypeptide originates from an early and/or late region of a papillomavirus.

25. The antitumoral composition according to claim 24, wherein said immunogenic polypeptide is derived from a polypeptide of the early region of a papillomavirus.

26. The antitumoral composition according to claim 25, wherein said immunogenic polypeptide is derived from an E6 or an E7 polypeptide of a papillomavirus.

27. The antitumoral composition according to claim 26, wherein said immunogenic polypeptide is derived from a nononcogenic variant of said E6 or E7 polypeptide of a papillomavirus.

28. The antitumoral composition according to claim 24, wherein said immunogenic polypeptide is derived from the L1 or L2 polypeptide of a papillomavirus.

29. The antitumoral composition according to claim 21, wherein at least one immunogenic polypeptide is derived from an early polypeptide and at least one immunogenic polypeptide is derived from a late polypeptide of a papillomavirus.

30. The antitumoral composition according to claim 21, wherein at least one immunogenic polypeptide is such that:

(1) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 1,

(2) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 2,

(3) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 1 and an immunogenic polypeptide having a sequence homologous or identical to that shown in SEQ ID NO: 2,

(4) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 1, an immunogenic polypeptide derived from the L1 protein of a

papillomavirus and/or an immunogenic polypeptide derived from the L2 protein of a papillomavirus,

(5) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 2, an immunogenic polypeptide derived from the L1 protein of a papillomavirus and/or an immunogenic polypeptide derived from the L2 protein of a papillomavirus, or

(6) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 1, an immunogenic polypeptide having a sequence homologous or identical to that shown in SEQ ID NO: 2, an immunogenic polypeptide derived from the L1 protein of a papillomavirus and/or an immunogenic polypeptide derived from the L2 protein of a papillomavirus.

31. The antitumoral composition according to claim 21, wherein said recombinant vector comprises, in addition, the sequences encoding at least one compound which enhances the antitumoral effect of said composition.

32. The antitumoral composition according to claim 31, wherein said compound enhancing the antitumoral effect is an immunostimulator.

33. The antitumoral composition according to claim 32, wherein said immunostimulator is selected from the group consisting of interleukin-2, interleukin-7, interleukin-12 and the coadhesion molecules B7.1 and B7.2.

34. The antitumoral composition according to claim 21, wherein said recombinant vector is derived from a poxvirus.

35. The antitumoral composition according to claim 21, containing a pharmaceutically acceptable carrier allowing its administration by injection into humans or into animals.

36. A recombinant vector comprising the sequences encoding one or more immunogenic polypeptide(s), wherein at least one of said polypeptides is a polypeptide of claim 21.

37. A viral particle comprising a recombinant vector according to claim 36.

38. An antitumoral composition, wherein said antitumoral composition comprises one or more immunogenic polypeptide(s), and wherein at least one of said polypeptides is a polypeptide of claim 21.

39. A method for the treatment or prevention of cancer or a tumor in a subject comprising administering an effective amount of the antitumoral composition of claim 21 to said subject to treat or prevent said cancer or tumor in said subject.